Juan Ramirez1, Carol Mason1, Juzar Ali1. 1. Division of Pulmonary, Critical Care Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana.
Abstract
INTRODUCTION: Mycobacterium avium complex (MAC) is a leading cause of pulmonary disease (PD), even in those with intact immunity, representing about 30% of the cases of pleuropulmonary mycobacterial infection. Based on previous studies, macrolides are the only agents used in the treatment of MAC disease for which there is a correlation between in vitro susceptibility and in vivo (clinical) response. However, resistance develops rapidly if single-agent treatment is used. Data regarding treatment of macrolide-resistant MAC (MRMAC) and multidrug-resistant MAC (MDRMAC) are sparse. CASE SUMMARY: A 50-year-old, HIV-negative white man, weighing 53.6 kg, with severe chronic obstructive pulmonary disease and bronchiectasis was initially on treatment for MAC-PD and MRMAC. The patient was followed between 1999 and 2006. His treatment history revealed that in addition to the multiple drugs administered during the course of his illness, thalidomide, interferon-γ, and mefloquine were also administered. The patient died ~7 years later due to respiratory failure and overwhelming infection CONCLUSIONS: This case report describes the use of mefloquine as adjunct treatment in an HIV-negative patient with MDRMAC-PD and discusses the associated outcomes of drug resistance.
INTRODUCTION:Mycobacterium avium complex (MAC) is a leading cause of pulmonary disease (PD), even in those with intact immunity, representing about 30% of the cases of pleuropulmonary mycobacterial infection. Based on previous studies, macrolides are the only agents used in the treatment of MAC disease for which there is a correlation between in vitro susceptibility and in vivo (clinical) response. However, resistance develops rapidly if single-agent treatment is used. Data regarding treatment of macrolide-resistant MAC (MRMAC) and multidrug-resistant MAC (MDRMAC) are sparse. CASE SUMMARY: A 50-year-old, HIV-negative white man, weighing 53.6 kg, with severe chronic obstructive pulmonary disease and bronchiectasis was initially on treatment for MAC-PD and MRMAC. The patient was followed between 1999 and 2006. His treatment history revealed that in addition to the multiple drugs administered during the course of his illness, thalidomide, interferon-γ, and mefloquine were also administered. The patient died ~7 years later due to respiratory failure and overwhelming infection CONCLUSIONS: This case report describes the use of mefloquine as adjunct treatment in an HIV-negative patient with MDRMAC-PD and discusses the associated outcomes of drug resistance.
Authors: David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop Journal: Am J Respir Crit Care Med Date: 2007-02-15 Impact factor: 21.405
Authors: David E Griffith; Barbara A Brown-Elliott; Brett Langsjoen; Yansheng Zhang; Xi Pan; William Girard; Kenwyn Nelson; James Caccitolo; Julio Alvarez; Sara Shepherd; Rebecca Wilson; Edward A Graviss; Richard J Wallace Journal: Am J Respir Crit Care Med Date: 2006-07-20 Impact factor: 21.405
Authors: E Tanaka; T Kimoto; K Tsuyuguchi; I Watanabe; H Matsumoto; A Niimi; K Suzuki; T Murayama; R Amitani; F Kuze Journal: Am J Respir Crit Care Med Date: 1999-09 Impact factor: 21.405
Authors: R E Chaisson; C A Benson; M P Dube; L B Heifets; J A Korvick; S Elkin; T Smith; J C Craft; F R Sattler Journal: Ann Intern Med Date: 1994-12-15 Impact factor: 25.391
Authors: Esteban C Nannini; Michael Keating; Peter Binstock; George Samonis; Dimitrios P Kontoyiannis Journal: J Infect Date: 2002-04 Impact factor: 6.072
Authors: D S Prince; D D Peterson; R M Steiner; J E Gottlieb; R Scott; H L Israel; W G Figueroa; J E Fish Journal: N Engl J Med Date: 1989-09-28 Impact factor: 91.245
Authors: R J Wallace; Y Zhang; B A Brown; D Dawson; D T Murphy; R Wilson; D E Griffith Journal: Am J Respir Crit Care Med Date: 1998-10 Impact factor: 21.405